MannKind | MNKD - Pre Tax Profit


MannKind reported $-20.93M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Insmed USD -326.93M 41.77M Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
MacroGenics USD -14.93M 31.75M Dec/2025
MannKind USD -20.93M 28.71M Dec/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Novo Nordisk DKK 25.52B 8.29B Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Xencor USD -4.27M 1.76M Dec/2025